INOVIO PHARMACEUTICALS, INC. (INO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 20M 40M 60M Q4 '10: 6.1M Q1 '11: 7.9M Q2 '11: 9.2M Q3 '11: 10.5M Q4 '11: 9.8M Q1 '12: 8.4M Q2 '12: 6.4M Q3 '12: 4.6M Q4 '12: 4.1M Q1 '13: 3.9M Q2 '13: 4.2M Q3 '13: 12.9M Q4 '13: 13.5M Q1 '14: 14.4M Q2 '14: 17.4M Q3 '14: 9.7M Q4 '14: 10.5M Q1 '15: 13.3M Q2 '15: 14.8M Q3 '15: 37.1M Q4 '15: 40.6M Q1 '16: 43.5M Q2 '16: 44.4M Q3 '16: 32.8M Q4 '16: 35.4M Q1 '17: 37.6M Q2 '17: 51.8M Q3 '17: 41.9M Q4 '17: 42.2M Q1 '18: 33.4M Q2 '18: 37.4M Q3 '18: 36.8M Q4 '18: 30.5M Q1 '19: 31.8M Q2 '19: 7.5M Q3 '19: 6.3M Q4 '19: 4.1M Q1 '20: 2.6M Q2 '20: 2.7M Q3 '20: 2.1M Q4 '20: 7.4M Q1 '21: 6.5M Q2 '21: 6.5M Q3 '21: 6.5M Q4 '21: 1.8M Q1 '22: 1.6M Q2 '22: 2.1M Q3 '22: 11M Q4 '22: 10.3M Q1 '23: 10.2M Q2 '23: 9.6M Q3 '23: 854K Q4 '23: 832K Q1 '24: 717.1K Q2 '24: 591.9K Q3 '24: 203.4K Q4 '24: 217.8K Q1 '25: 283.1K Q2 '25: 182.3K Q3 '25: 182.3K Q4 '25: 65.3K Q1 '26: 0 Q2 '26: 0 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '10: -19.2M Q1 '11: -19.2M Q2 '11: -19.4M Q3 '11: -21.1M Q4 '11: -21.6M Q1 '12: -21.4M Q2 '12: -23.1M Q3 '12: -23M Q4 '12: -23.5M Q1 '13: -25.9M Q2 '13: -24.8M Q3 '13: -17.8M Q4 '13: -19.5M Q1 '14: -22.9M Q2 '14: -27.4M Q3 '14: -36.5M Q4 '14: -39.5M Q1 '15: -37.9M Q2 '15: -42.8M Q3 '15: -30.8M Q4 '15: -34.3M Q1 '16: -41.4M Q2 '16: -44.5M Q3 '16: -68.4M Q4 '16: -76.2M Q1 '17: -82.7M Q2 '17: -74.1M Q3 '17: -83.1M Q4 '17: -83.6M Q1 '18: -94.5M Q2 '18: -90M Q3 '18: -87.5M Q4 '18: -94.1M Q1 '19: -89.9M Q2 '19: -112.9M Q3 '19: -110.2M Q4 '19: -111.1M Q1 '20: -107.8M Q2 '20: -112.8M Q3 '20: -125.2M Q4 '20: -124.1M Q1 '21: -151.4M Q2 '21: -201.4M Q3 '21: -225M Q4 '21: -301.2M Q1 '22: -320.4M Q2 '22: -341.3M Q3 '22: -317.1M Q4 '22: -267.6M Q1 '23: -239.8M Q2 '23: -172.7M Q3 '23: -172.5M Q4 '23: -143.9M Q1 '24: -131.5M Q2 '24: -127.6M Q3 '24: -119.4M Q4 '24: -112.4M Q1 '25: -106M Q2 '25: -95.9M Q3 '25: -89.7M Q4 '25: -86.8M Q1 '26: -83.7M Q2 '26: -79.3M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '10: -17.6M Q1 '11: -17.7M Q2 '11: -12.9M Q3 '11: -16.1M Q4 '11: -15.3M Q1 '12: -21.1M Q2 '12: -22.4M Q3 '12: -24.5M Q4 '12: -19.7M Q1 '13: -20.3M Q2 '13: -27M Q3 '13: -51.2M Q4 '13: -66M Q1 '14: -68M Q2 '14: -67.9M Q3 '14: -44.2M Q4 '14: -36.1M Q1 '15: -35.9M Q2 '15: -31.4M Q3 '15: -18.6M Q4 '15: -29.2M Q1 '16: -26.6M Q2 '16: -39.1M Q3 '16: -65.5M Q4 '16: -73.7M Q1 '17: -88.8M Q2 '17: -79.6M Q3 '17: -92.9M Q4 '17: -88.2M Q1 '18: -97.5M Q2 '18: -94.6M Q3 '18: -85.5M Q4 '18: -97M Q1 '19: -93.8M Q2 '19: -116.6M Q3 '19: -114.7M Q4 '19: -119.4M Q1 '20: -122.7M Q2 '20: -222M Q3 '20: -179.7M Q4 '20: -166.4M Q1 '21: -188.3M Q2 '21: -141.7M Q3 '21: -221M Q4 '21: -303.7M Q1 '22: -328.3M Q2 '22: -354.7M Q3 '22: -332.3M Q4 '22: -279.8M Q1 '23: -241.4M Q2 '23: -168.4M Q3 '23: -164.6M Q4 '23: -135.1M Q1 '24: -124.9M Q2 '24: -121.6M Q3 '24: -112.9M Q4 '24: -107.3M Q1 '25: -96.5M Q2 '25: -87.8M Q3 '25: -108.1M Q4 '25: -84.9M Q1 '26: -84.9M Q2 '26: -67.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '11: -14.1M Q3 '11: -18.6M Q4 '11: -19.8M Q1 '12: -19.7M Q2 '12: -20.6M Q3 '12: -21.3M Q4 '12: -22.3M Q1 '13: -22M Q2 '13: -22.1M Q3 '13: -21.8M Q4 '13: -15.4M Q1 '14: -15.8M Q2 '14: -18.5M Q3 '14: -20.9M Q4 '14: -29.8M Q1 '15: -36.3M Q2 '15: -37.2M Q3 '15: -13.7M Q4 '15: -12.4M Q1 '16: -16.1M Q2 '16: -20.4M Q3 '16: -54.4M Q4 '16: -62.6M Q1 '17: -62M Q2 '17: -65.5M Q3 '17: -64.2M Q4 '17: -63.2M Q1 '18: -60.6M Q2 '18: -62.9M Q3 '18: -70.2M Q4 '18: -73.6M Q1 '19: -93.4M Q2 '19: -98.3M Q3 '19: -101.4M Q4 '19: -97.9M Q1 '20: -90.8M Q2 '20: -94.1M Q3 '20: -140.5M Q4 '20: -178M Q1 '21: -205.4M Q2 '21: -256.7M Q3 '21: -229M Q4 '21: -215.7M Q1 '22: -224.7M Q2 '22: -196.8M Q3 '22: -217.8M Q4 '22: -216.2M Q1 '23: -191M Q2 '23: -172.8M Q3 '23: -134.4M Q4 '23: -124.4M Q1 '24: -116.5M Q2 '24: -112.4M Q3 '24: -110.7M Q4 '24: -104.1M Q1 '25: -102.2M Q2 '25: -94.8M Q3 '25: -88.9M Q4 '25: -88.6M Q1 '26: -83.3M Q2 '26: -80.6M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '11: -14.2M Q3 '11: -18.7M Q4 '11: -19.9M Q1 '12: -19.9M Q2 '12: -20.8M Q3 '12: -21.6M Q4 '12: -22.5M Q1 '13: -22.2M Q2 '13: -22.2M Q3 '13: -22.1M Q4 '14: -31.2M Q1 '15: -38.1M Q2 '15: -38.9M Q3 '15: -15.9M Q4 '15: -15.2M Q1 '16: -19M Q2 '16: -24.2M Q3 '16: -57.9M Q4 '16: -65.3M Q1 '17: -64.9M Q2 '17: -71.9M Q3 '17: -73.6M Q4 '17: -73.5M Q1 '18: -71.2M Q2 '18: -68.9M Q3 '18: -72.8M Q4 '18: -75.6M Q1 '19: -95M Q2 '19: -99.5M Q3 '19: -102.6M Q4 '19: -98.8M Q1 '20: -91.3M Q2 '20: -94.5M Q3 '20: -141.2M Q4 '20: -179.5M Q1 '21: -207M Q2 '21: -258.5M Q3 '21: -230.6M Q4 '21: -216.9M Q1 '22: -225.7M Q2 '22: -198.3M Q3 '22: -219.2M Q4 '22: -217.2M Q1 '23: -192.3M Q2 '23: -173.4M Q3 '23: -134.9M Q4 '23: -124.7M Q1 '24: -116.5M Q2 '24: -112.8M Q3 '24: -111.2M Q4 '24: -104.6M Q1 '25: -102.7M Q2 '25: -94.9M Q3 '25: -89.1M Q4 '25: -88.9M Q1 '26: -83.6M Q2 '26: -80.8M Q2 '11 Q2 '13 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q1 '13: 39M Q2 '13: 45M Q3 '13: 48M Q4 '13: 52.1M Q1 '14: 55.2M Q2 '14: 60.5M Q3 '14: 60.6M Q4 '14: 60.8M Q1 '15: 60.9M Q2 '15: 67.8M Q3 '15: 74M Q4 '15: 72.2M Q1 '16: 72.2M Q2 '16: 73M Q3 '16: 73.8M Q1 '17: 74.3M Q2 '17: 75.4M Q3 '17: 87.1M Q1 '18: 90.5M Q2 '18: 91.2M Q3 '18: 92.4M Q2 '19: 98.1M Q3 '19: 102.8M Q2 '20: 155.8M Q3 '20: 174.4M Q1 '21: 202.4M Q2 '21: 209.6M Q3 '21: 210.3M Q1 '22: 218.9M Q2 '22: 235.3M Q3 '22: 249.4M Q1 '23: 21.5M Q2 '23: 22M Q3 '23: 22.4M Q1 '24: 23.3M Q2 '24: 27.2M Q3 '24: 28.1M Q1 '25: 38.6M Q2 '25: 38.8M Q3 '25: 52.2M Q1 '26: 69.1M Q2 '26: 81.6M Q2 '14 Q4 '15 Q3 '17 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q4 '10: -0.17 Q1 '11: -0.16 Q2 '11: -0.11 Q3 '11: -0.14 Q4 '11: -0.12 Q1 '12: -0.16 Q2 '12: -0.17 Q3 '12: -0.18 Q4 '12: -0.14 Q1 '13: -0.31 Q2 '13: -0.52 Q3 '13: -1.11 Q4 '13: -1.41 Q1 '14: -1.38 Q2 '14: -1.33 Q3 '14: -0.81 Q4 '14: -0.63 Q1 '15: -0.61 Q2 '15: -0.51 Q3 '15: -0.32 Q4 '15: -0.45 Q1 '16: -0.38 Q2 '16: -0.55 Q3 '16: -0.90 Q4 '16: -1.01 Q1 '17: -1.21 Q2 '17: -1.08 Q3 '17: -1.20 Q4 '17: -1.08 Q1 '18: -1.13 Q2 '18: -1.08 Q3 '18: -0.95 Q4 '18: -1.05 Q1 '19: -0.99 Q2 '19: -1.21 Q3 '19: -1.19 Q4 '19: -1.23 Q1 '20: -1.19 Q2 '20: -1.72 Q3 '20: -1.36 Q4 '20: -1.12 Q1 '21: -1.13 Q2 '21: -0.69 Q3 '21: -1.09 Q4 '21: -17.45 Q1 '22: -17.54 Q2 '22: -17.61 Q3 '22: -17.47 Q4 '22: -14.08 Q1 '23: -15.61 Q2 '23: -16.76 Q3 '23: -18.13 Q4 '23: -6.10 Q1 '24: -5.52 Q2 '24: -5.10 Q3 '24: -4.47 Q4 '24: -3.99 Q1 '25: -3.19 Q2 '25: -2.61 Q3 '25: -2.59 Q4 '25: -1.81 Q1 '26: -1.58 Q2 '26: -1.04 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.